Hot off the Forge
-
“Forge’s AAV-specific manufacturing expertise and platform technologies give us confidence in a smooth path forward in the development of AVST-101,”…
-
Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl’s pancreatic gene therapy platform for patients with…
-
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing…
-
“We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene therapy.”
-
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and…
-
John Maslowski, Chief Commercial Officer, to succeed Dr. Timothy Miller as President and CEO. “It’s an exciting time at Forge.”
-
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon…
-
“As we continue to advance how genetic medicines are manufactured, we are thrilled to present data showcasing our novel molecular…
-
Designation grants Forge’s FBX-101 therapy access to enter the Innovative Licensing and Access Pathway (ILAP).
-
Five patients have received FBX-101, all of whom were identified by newborn screening.
-
Research findings indicate a path to the development of potentially safer adeno-associated virus (AAV) gene therapies.
-
Acquisition positions Forge for accelerated long-term growth supporting gene and cell therapy clients worldwide.